ATL1103 Clinical Development Update
Antisense Therapeutics Limited (ANP) is pleased to advise that preparations for the first human trial of ATL1103, the Company’s drug that is designed to block growth hormone receptor expression, are on track with the formulation of raw material into injectible product to be used in the trial having been successfully completed on schedule.
The next step for ANP, as outlined in the Company’s ASX announcement on the 21st February 2011, is to make an application for approval to conduct the clinical trial.
The trial will be undertaken by an experienced Clinical Research Organisation (CRO) at a clinical trial unit in Australia. The application will be made to the clinical trial unit’s hospital ethics committee. ANP expect to submit the trial application and receive approval for a planned trial commencement Q3 2011 – as advised in the 21 February announcement.
The first (single ascending dose) stage of the Phase I safety and tolerability trial of ATL1103 in ealthy volunteers remains on course to be completed by the end of 2011.
ATL1103 is being developed by ANP for particular growth and sight disorders as well as some forms of cancer.
Download this document
